Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
CAXTON CORP (CIK 1388551) reported $4.0M across 7 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: GLD ($3.3M, 81.50%), BRK/B ($348,341, 8.66%), KYTX ($162,012, 4.03%), LXEO ($80,032, 1.99%), XFOR ($64,249, 1.60%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | GLD | SPDR GOLD TR | $3.3M | 81.50% | 7,623 | Added |
| 2 | BRK/B | BERKSHIRE HATHAWAY INC DEL | $348,341 | 8.66% | 727 | Added |
| 3 | KYTX | KYVERNA THERAPEUTICS INC | $162,012 | 4.03% | 18,773 | Hold |
| 4 | LXEO | LEXEO THERAPEUTICS INC | $80,032 | 1.99% | 13,943 | Hold |
| 5 | XFOR | X4 PHARMACEUTICALS INC | $64,249 | 1.60% | 15,557 | Hold |
| 6 | IKT | INHIBIKASE THERAPEUTICS INC | $47,801 | 1.19% | 28,453 | Hold |
| 7 | ALXO | ALX ONCOLOGY HLDGS INC | $41,996 | 1.04% | 20,946 | New |
| 8 | SYRE | SPYRE THERAPEUTICS INC | $0 | 0.00% | 0 | Exited |
| 9 | CMPX | COMPASS THERAPEUTICS INC | $0 | 0.00% | 0 | Exited |
| 10 | CNTX | CONTEXT THERAPEUTICS INC | $0 | 0.00% | 0 | Exited |
| 11 | MNMD | MIND MEDICINE MINDMED INC | $0 | 0.00% | 0 | Exited |
| 12 | SABS | SAB BIOTHERAPEUTICS INC | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-03-31